Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NUOT, was pumped from $0.05 a few days ago, LOL!
Unreal, wish i could have grabbed some
NUOT, Huge Loss: Net loss of $13.8 million, compared with a net loss of $4.8 million in the third quarter of 2014
And exit with over 50% gain.
Ready to reload.
Woof there's that derivative effect again
One of you in the know guys please explain what the derivative risk is exactly
It still looks to me to be part of a toxic convert financing now partially released by changing the loan terms and conversion price
WOW NUOT HIT .08'S TODAY
Tomorrow, I guess we will have the announcement that they will report financial results of the third quarter of 2015
It will be interesting starting tomorrow to see if we can reach the 52 week high.
Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced that it will report financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of market.
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the Aurix™ System reimbursement rate under the Hospital Outpatient Prospective Payment System (HOPPS) for the calendar year 2016 has been published by the Centers for Medicare and Medicaid Services (CMS). Aurix was placed in Ambulatory Payment Classification (APC) 5054 (Level 4 Skin Procedures) and will be reimbursed at a national average rate of $1,411 per application effective January 1, 2016. In the text of the ruling, CMS commented they believe the geometric mean cost of the services underlying Aurix is comparable to the geometric mean cost of APC 5054.
Nuo Therapeutics Responds to Favorable CMS Hospital Outpatient Payment Final Ruling for Aurix System
Jason Napodano, CFA Nov 4
Heck of a run in $NUOT the past two days. I spoke with Dean earlier. Medicare is back on the table after that super-positive CMS decision.
NUOT give me that HOD
NUOT .25-.29 tomorrow peak imo
NUOT .20 BOOOOOOOOOOM
NUOT .20-.25 today?
Looking good so far, still think .20 as soon as tomorrow
NUOT .11 huge loading, .20+ coming
NUOT gut feeling it hits .20 in the next day or 2 imo
Solid news today from NUOT. Stock price is starting to move.
Looks like those negotiations didn't go well
Before the meeting stock went up to .09 on volume
Since the meeting it has died
Part of managements role is to raise capital, these guys aren't very good at that
Management has been in contact with Deerfield and intends to engage promptly in substantive discussions with Deerfield to modify the facility agreement, if possible, and avoid these technical defaults thereby permitting us to continue our operations. We cannot provide any assurance that Deerfield will agree to modify the facility agreement, whether any proposed modifications to the agreement would be on terms favorable, or acceptable, to us, or whether Deerfield will declare an event of default under the agreement and foreclose on our assets by enforcing their rights under the security agreement. If we cannot agree on modifications to the facility agreement, we may be required to cease operations or, alternatively, seek protection under federal bankruptcy statutes. Even if we can reach an agreement to modify the facility agreement in a manner that is acceptable to us, management believes that we will be required to identify additional sources of capital to continue our operations beyond December 31, 2015.
Yea, as I said I was in this as a bounce play. I did not look deep into the financials. Got in at .0432 and out at .075. Take care.
What sort of loan has a dervitave risk?
$16mm?
If it's a toxic convert its all over
It was a less then $20 paint job, not 200 dollars. A 300 share trade end of day made the stock close down 23%. Sorry for the mistake. I thought it was a 3000 share paint. It was not. It was 300 shares. It was also done end of day. Only reason I can see for someone selling 18 dollars worth of stock and do it end of day is to try and manipulate the chart.
That is their loan with Deerfield I believe you are talking about. I bought this right at bottom. Stock has been trading clean and very thin. Buys were almost 4 to 1 to sells yesterday but a less then 200 dollar paint job end of day yesterday had the stock close more then 20% down. I mainly bought this for a chart play btw.
So what is the 'derivative risk'??
Is that part of some ill advised toxic convert?
If they did one it all over, the investor gets more stock with each downtick..
RSI wasn't gonna stay at 10 forever
The clawback has been steady and the Quarterly revs unrefutable.
Have a great weekend !
Wanted to let you know that you are not here by yourself. I have been in since 4 cents, and I am still in. It has been a little slow but it has been marching along. I agree it was a great week. Enjoy your weekend.
NEWS : VA Commercialization
************************************************
uo Therapeutics Provides Updates on VA Commercialization Efforts
Globe Newswire
August 26, 2015: 08:30 AM ET
GAITHERSBURG, Md., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced several updates related to its focus on making the Company's chronic wound care solution, Aurix™, broadly available to facilities within the Department of Veterans Affairs (VA) Healthcare System.
Aurix is now available on the Federal Supply Schedule
Aurix to be featured in Product Showcase at 2015 PVA Summit + Expo
Nuo bolsters VA-dedicated sales team
Aurix is Now Available on the Federal Supply Schedule
Earlier this month, the Company successfully added Aurix, under its new brand name, to the Federal Supply Schedule (FSS). While the product has been listed on the FSS contract under its former brand name, this contract modification supports the Company's continued focus on ensuring uncomplicated access for all FSS-eligible patients and purchasers, including the VA Healthcare System and Indian Health Services.
"Inclusion of Aurix by name on our FSS contract is a significant achievement as we continue to increase our commercial focus on the VA," said Dean Tozer, President and Chief Executive Officer of Nuo Therapeutics. "With 10 federal healthcare facilities already treating patients with Aurix, we have made significant progress in this market. However, we believe having Aurix specifically listed with the current brand name on the FSS will help facilitate further purchasing of the product among healthcare providers in the VA."
The modification is effective as of August 15, 2015, and is added to the Company's existing FSS contract (V797P-4001B), issued by the VA National Acquisition Center.
Aurix to be Featured in Product Showcase at 2015 PVA Summit + Expo
Additionally, Nuo Therapeutics will continue its support of the Paralyzed Veterans of America (PVA) by participating in the 5th Annual PVA Summit + Expo, to be held on September 1 – 3 in Jacksonville, FL.
The Company will host a Product Showcase, during which Peter A. Clausen, Ph.D., Chief Scientific Officer of Nuo Therapeutics, and Cesar H. Porta, M.D., Certified Wound Specialist Physician at United Regional Health Care System in Wichita Falls, TX, will review the scientific and clinical benefits of Aurix. The session will take place on Tuesday, September 1st from 12:00 to 1:00 p.m.
In addition, Nuo Therapeutics representatives will be available at booth #400 to discuss the benefits of Aurix for use in treating pressure ulcers and pressure-related wounds that often result from mobility impairment.
Now in its fifth year, the PVA Summit provides information on state-of-the-art research and emerging science that can be put to immediate use in caring for individuals with spinal cord injury/disease (SCI/D), Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS) and traumatic brain injury (TBI). Each year, attendees represent multiple disciplines from the VA as well as private healthcare institutions.
Nuo Therapeutics Bolsters VA-Dedicated Sales Team
Finally, in further support of its VA-focused commercial efforts, the Company previously announced the addition of several sales professionals dedicated to the VA market, bringing the total representative count to eight.
About Nuo Therapeutics
Nuo Therapeutics, Inc. (the "Company") is a biomedical company that pioneers leading-edge biodynamic therapies for wound care. The Company's flagship product, Aurix is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. For additional information please visit www.nuot.com.
About Aurix
Aurix is the first platelet and plasma therapy system to be cleared by FDA for the management of a broad range of ulcers and exuding wounds, including:
All types (diabetic foot ulcer, venous leg ulcer, pressure ulcer, etc.),
All morphologies (partial thickness, full thickness and complex wounds),
All severities (tunneling, sinus tract, bone, tendon and hardware exposure).
Unlike other cellular-based treatment options, Aurix is an autologous biodynamic hematogel that is derived from a patient's own platelets and plasma. The product is used at the point-of-care to stimulate the natural wound healing process from deep within the wound bed. For additional information, please visit www.AurixSystem.com.
Looking for a dead cat bounce. See ya at trips
Looking for a dead cat bounce. See ya at trips
'Derivative risk' is that a toxic convert?
If it is this is going to zero as planned by investor
'Short attack' 'someone wants it lower to load up'
You're kidding right?
Lender doesn't surrender rights and overpriced prima Donna management won't give up salaries then lender takes the technology for $16,000,000 'derivative risk' ie: toxic convert
Dead cat bounce ( light volume relative to sell off)
RSI still only 16
pretty low levels.
True that. Easy money.
$3Million in Quarterly Earnings... Should get Credit Facility
Just some old debts that should be easy to clear if the
the right Private Investor steps up and realizes the potential
future value here.
Volume returned to normal... Price going back up.
Few more days til we see pre-sell off levels?
Still way way oversold OTCQX whaaaat?!
Designed for investor-focused companies that meet high financial standards, are current in their disclosure and receive third party advisory. The companies found on OTCQX are distinguished by the excellence of their operations and diligence with which they convey their qualifications.
$NUOT, dump over, green days and short squeeeze!
Then that means the drop in pps is attributed to the Deerfield agreement.
Good to know. Thanks
Followers
|
37
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
840
|
Created
|
02/08/06
|
Type
|
Free
|
Moderators |
Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies for wound care.
The Company's flagship product, Aurix is a biodynamic hematogel that harnesses a patient's innate
regenerative abilities for the management of a variety of wounds.
(NUOTQ) Nuo Therapeutics, Inc.
http://www.nuot.com/
info@nuot.com
HQ OFFICE : 207A Perry Parkway, Suite 1, Gaithersburg, MD 20877
Phone: 1-866-298-6633 Fax: 1-240-499-2690
FOR INVESTOR RELATED QUESTIONS CONTACT
Lindsey Saxon: 240-685-5004
Bankruptcy
NEWS
Nuo Therapeutics Provides Update on Chapter 11 Bankruptcy Process and Proposed Plan of Reorganization
March 29. 2016
Nuo Therapeutics Inc. Commences Voluntary Chapter 11 Business Reorganization
Jan. 26, 2016
MORE NEWS
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |